AKTX
Akari Therapeutics·NASDAQ
--
--(--)
--
--(--)
AKTX fundamentals
During Q3 2025, Akari Therapeutics (AKTX) reported revenue of --, a YoY change of 0.00%. Net income was -6.40M, a YoY change of -121.07%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2015 | Q2,2015 | Q3,2015 | Q4,2015 | Q1,2016 | Q2,2016 | Q2,2017 | Q3,2017 | Q4,2017 | Q1,2018 | Q3,2018 | Q4,2018 | Q1,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jan 1, 2015 | Apr 1, 2015 | Jul 1, 2015 | Oct 1, 2015 | Jan 1, 2016 | Apr 1, 2016 | Apr 1, 2017 | Jul 1, 2017 | Oct 1, 2017 | Jan 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Mar 31, 2015 | Jun 30, 2015 | Sep 30, 2015 | Dec 31, 2015 | Mar 31, 2016 | Jun 30, 2016 | Jun 30, 2017 | Sep 30, 2017 | Dec 31, 2017 | Mar 31, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 1.65M -- | 1.46M -- | 23.33M -- | 4.29M -- | 3.85M +132.80% | 7.52M +416.48% | 7.35M -2.27% | 8.54M -- | 13.61M -- | 4.31M -- | 2.99M -65.04% | 5.52M -59.48% | -11.96K -100.28% | 4.93M +41288.55% | 5.91M -- | 246.88K -- | 6.90M -- | 5.55M +12.62% | 4.33M -26.75% | 1.46M +492.75% | 5.87M -14.84% | 5.24M -5.49% | 5.82M +34.32% | 4.59M -12.39% | 4.62M -20.65% | 2.51M -- | 5.09M -- | 5.99M +30.37% | 7.45M +61.41% | 2.93M +16.75% | 5.28M +3.69% | 3.52M -41.14% | 3.12M -58.13% | 7.40M +152.96% | 19.33M -- |
Selling, General and Administrative Expenses | 99.68K -- | 1.31M -- | 2.73M -- | 2.36M -- | 2.35M +2260.01% | 2.08M +58.05% | 3.57M +71.75% | 2.16M -- | 3.79M -- | 3.30M -- | 2.38M +10.35% | 3.15M -16.88% | 2.31M -30.04% | 2.19M -4.84% | 2.89M -- | 1.84M -- | 2.24M -- | 2.02M -8.00% | 2.15M -25.75% | 1.89M +2.94% | 2.02M -9.58% | 3.10M +53.74% | 2.97M +38.12% | 2.86M -7.78% | 3.09M +4.25% | 2.82M -- | 2.58M -- | 3.71M +29.58% | 2.24M -27.50% | 1.71M -39.42% | 3.05M +18.09% | 2.71M -26.90% | 2.45M +9.42% | 1.98M +15.56% | 10.19M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 9.16M -- | -- -- | -- -- | -- -- | 8.08M -11.79% | -- -- | -- -- | -- -- | -- -- | 2.82M -- | 2.58M -- | 3.71M -- | 2.24M -- | 1.71M -39.42% | 3.05M +18.09% | 2.71M -26.90% | 2.45M +9.42% | 1.98M +15.56% | 10.19M -- |
Research and Development Expenses | 1.55M -- | 142.00K -- | 1.31M -- | 1.93M -- | 1.50M -3.56% | 5.44M +3733.17% | 3.78M -30.51% | 6.38M -- | 7.12M -- | 1.01M -- | 3.30M -48.24% | 2.36M -66.81% | -2.32M -329.91% | 2.73M +217.85% | 3.02M -- | -1.59M -- | 4.66M -- | 3.53M +29.18% | 2.18M -27.71% | -430.16K +72.99% | 3.85M -17.37% | 2.14M -39.38% | 2.85M +30.58% | 1.73M -19.10% | 1.52M -46.55% | -314.00K -- | 2.51M -- | 2.28M +31.66% | 3.31M +117.45% | 143.00K +145.54% | 1.25M -50.30% | 813.00K -64.33% | 667.00K -79.87% | 249.00K +74.13% | 2.98M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 5.18M -- | -- -- |
Other Operating Expenses | -- -- | -- -- | 19.28M -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 2.70M -- | -- -- | -2.70M -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | 1.89M -- | 1.07M -- | 983.00K -- | -- -- | 0 -100.00% | 0 -100.00% | -- -- |
Operating Income | -1.65M -- | -1.46M -- | -23.33M -- | -4.29M -- | -3.85M -132.80% | -7.52M -416.48% | -7.35M +2.27% | -8.54M -- | -13.61M -- | -4.31M -- | -2.99M +65.04% | -5.52M +59.48% | 11.96K +100.28% | -4.93M -41288.55% | -5.91M -- | -246.88K -- | -6.90M -- | -5.55M -12.62% | -4.33M +26.75% | -1.46M -492.75% | -5.87M +14.84% | -5.24M +5.49% | -5.82M -34.32% | -4.59M +12.39% | -4.62M +20.65% | -2.51M -- | -5.09M -- | -5.99M -30.37% | -7.45M -61.41% | -2.93M -16.75% | -5.28M -3.69% | -3.52M +41.14% | -3.12M +58.13% | -7.40M -152.96% | -19.33M -- |
Non-Operating Income (Loss) | -42.16K -- | -215.00K -- | -25.41M -- | 10.76M -- | 866.59K +2155.63% | 1.07M +596.99% | 7.03M +557.84% | -1.84M -- | 1.49M -- | 2.97M -- | -607.31K +66.91% | -2.03M -236.04% | -2.56M -186.20% | 1.18M +146.20% | -1.53M -- | 1.16M -- | 85.66K -- | -289.83K -124.53% | -16.33K +98.93% | 12.04K -98.96% | 84.02K -1.91% | 67.59K +123.32% | 136.17K +933.68% | 5.59M +8177.85% | 615.00K +351.63% | -364.00K -- | 952.00K -- | 423.00K -92.44% | -109.00K -117.72% | 32.00K +108.79% | 1.51M +58.19% | -180.00K -142.55% | 1.22M +1222.94% | -84.00K -362.50% | 2.47M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 556.81K -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -258.00K -- | 710.00K -- | 649.00K -- | -151.00K -- | 30.00K +111.63% | 1.56M +119.30% | -54.00K -108.32% | 134.00K +188.74% | 253.00K +743.33% | 1.89M -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 350.94K -- | -- -- | -- -- | -- -- | -193.22K -155.06% | -- -- | -- -- | -- -- | -- -- | -100.00K -- | 208.00K -- | -226.00K -- | 91.00K -- | 68.00K +168.00% | 73.00K -64.90% | -125.00K +44.69% | -50.00K -154.95% | 76.00K +11.76% | -26.00K -- |
Other Non-Operating Income (Loss) | -37.60K -- | -- -- | 617.24K -- | 10.74M -- | 835.79K +2322.79% | 1.05M -- | 6.99M +565.00% | -1.88M -- | 1.44M -- | 2.90M -- | -673.38K +64.23% | -2.05M -242.52% | -2.56M -188.16% | 1.18M +146.14% | -1.53M -- | 1.15M -- | -827.41K -- | -293.57K -124.87% | -17.85K +98.83% | 10.67K -99.08% | 273.26K +133.03% | 63.23K +121.54% | 132.22K +840.76% | 5.57M +8701.48% | 586.00K +343.20% | -22.00K -- | 27.00K -- | -2.00K -100.04% | 0 -100.00% | 0 +100.00% | -1.00K -103.70% | 54.00K +2800.00% | 1.19M -- | -293.00K -- | 950.00K -- |
Net Interest Expense | 4.56K -- | 215.00K -- | 26.03M -- | -25.21K -- | -30.80K -776.12% | -17.31K -108.05% | -38.56K -122.82% | -46.91K -- | -51.04K -- | -64.64K -- | -66.07K -40.86% | -24.11K +52.76% | -1.29K +98.01% | -1.01K +21.46% | -1.15K -- | -6.13K -- | -5.32K -- | -3.73K -269.80% | -1.51K -31.51% | -1.37K +77.64% | -3.98K +25.22% | -4.36K -16.79% | -3.96K -161.06% | -30.00K -587.76% | -29.00K -633.25% | -16.00K -- | -7.00K -- | -2.00K +93.33% | 49.00K +268.97% | 66.00K +512.50% | 123.00K +1857.14% | 55.00K +2850.00% | 50.00K +2.04% | 120.00K +81.82% | 348.00K -- |
Interest Expense | 4.56K -- | -- -- | 26.03M -- | -5.95K -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | 51.00K -- | 69.00K -- | 124.00K -- | 55.00K -- | 50.00K -1.96% | 121.00K +75.36% | 350.00K -- |
Interest Income | 0 -- | -- -- | 1.45K -- | 19.26K -- | 30.80K -- | 17.31K -- | 38.56K +122.82% | 46.91K -- | 51.04K -- | 64.64K -- | 66.07K +40.86% | 24.11K -52.76% | 1.29K -98.01% | 1.01K -21.46% | 1.15K -- | 6.13K -- | 5.32K -- | 3.73K +269.80% | 1.51K +31.51% | 1.37K -77.64% | 3.98K -25.22% | 4.36K +16.79% | 3.96K +161.06% | 30.00K +587.76% | 29.00K +633.25% | 16.00K -- | 7.00K -- | 2.00K -93.33% | 2.00K -93.10% | 3.00K -81.25% | 1.00K -85.71% | 0 -100.00% | 0 -100.00% | 1.00K -66.67% | 2.00K -- |
Pretax Income From Continuing Operations | -1.70M -- | -1.67M -- | -48.74M -- | 6.47M -- | -2.99M -75.94% | -6.45M -286.08% | -320.02K +95.04% | -10.38M -- | -12.12M -- | -1.34M -- | -3.59M +65.37% | -3.51M +71.01% | -2.55M -90.15% | -3.75M -47.15% | -7.44M -- | 913.45K -- | -6.81M -- | -5.84M -55.88% | -4.35M +41.58% | -1.45M -258.89% | -5.79M +15.00% | -5.18M +11.34% | -5.68M -30.68% | 1.00M +119.34% | -4.00M +29.58% | -2.87M -- | -4.14M -- | -5.57M -656.04% | -7.56M -88.95% | -2.90M -0.84% | -3.77M +8.84% | -3.71M +33.44% | -1.90M +74.93% | -7.49M -158.65% | -16.86M -- |
Income Tax Expense | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -1.09M -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -1.09M -- | -- -- |
Net Income | -1.70M -- | -1.67M -- | -48.74M -- | 6.47M -- | -2.99M -75.94% | -6.45M -286.08% | -320.02K +95.04% | -10.38M -- | -12.12M -- | -1.34M -- | -3.59M +65.37% | -3.51M +71.01% | -2.55M -90.15% | -3.75M -47.15% | -7.44M -- | 913.45K -- | -6.81M -- | -5.84M -55.88% | -4.35M +41.58% | -1.45M -258.89% | -5.79M +15.00% | -5.18M +11.34% | -5.68M -30.68% | 1.00M +119.34% | -4.00M +29.58% | -2.87M -- | -4.14M -- | -5.57M -656.04% | -7.56M -88.95% | -2.90M -0.84% | -3.77M +8.84% | -3.71M +33.44% | -1.90M +74.93% | -6.40M -121.07% | -15.77M -- |
Net Income Attributable to Owners of the Company | -1.70M -- | -1.67M -- | -48.74M -- | 6.47M -- | -2.99M -75.94% | -6.45M -286.08% | -320.02K +95.04% | -10.38M -- | -12.12M -- | -1.34M -- | -3.59M +65.37% | -7.55M +37.73% | -2.55M -90.15% | -3.75M -47.15% | -7.44M -- | 913.45K -- | -6.81M -- | -5.84M -55.88% | -4.35M +41.58% | -1.45M -258.89% | -5.79M +15.00% | -5.18M +11.34% | -5.68M -30.68% | 1.00M +119.34% | -4.00M +29.58% | -2.87M -- | -4.14M -- | -5.57M -656.04% | -7.56M -88.95% | -2.90M -0.84% | -3.77M +8.84% | -3.71M +33.44% | -1.90M +74.93% | -6.40M -121.07% | -15.77M -- |
Net Income Attributable to Common Stockholders | -1.70M -- | -1.67M -- | -48.74M -- | 6.47M -- | -2.99M -75.94% | -6.45M -286.08% | -320.02K +95.04% | -10.38M -- | -12.12M -- | -1.34M -- | -3.59M +65.37% | -7.55M +37.73% | -2.55M -90.15% | -3.75M -47.15% | -7.44M -- | 913.45K -- | -6.81M -- | -5.84M -55.88% | -4.35M +41.58% | -1.45M -258.89% | -5.79M +15.00% | -5.18M +11.34% | -5.68M -30.68% | 1.00M +119.34% | -4.00M +29.58% | -2.87M -- | -4.14M -- | -5.57M -656.04% | -7.56M -88.95% | -2.90M -0.84% | -3.77M +8.84% | -3.71M +33.44% | -1.90M +74.93% | -6.40M -121.07% | -15.77M -- |
Other Comprehensive Income | 23.86K -- | -- -- | -43.26K -- | -40.61K -- | -192.94K -908.82% | -155.41K -- | -48.58K +68.74% | 85.43K -- | 52.15K -- | 32.80K -- | -65.85K -177.08% | -55.94K -207.27% | 107.17K +226.74% | -222.72K -307.83% | -46.04K -- | -3.68K -- | -26.77K -- | 306.10K +237.43% | -78.12K -69.69% | -27.33K -643.44% | -93.55K -249.50% | -32.35K -110.57% | -48.24K +38.25% | 2.00K +106.18% | -57.00K -18.16% | -3.00K -- | -211.00K -- | 279.00K +13850.00% | 12.00K +121.05% | -177.00K -5800.00% | 188.00K +189.10% | -35.00K -112.54% | -333.00K -2875.00% | -38.00K +78.53% | -218.00K -- |
Total Comprehensive Income | -1.67M -- | -1.67M -- | -48.78M -- | 6.43M -- | -3.18M -89.99% | -6.61M -295.38% | -368.59K +94.42% | -10.29M -- | -12.07M -- | -1.31M -- | -3.66M +64.44% | -3.57M +70.42% | -2.44M -86.72% | -3.97M -62.75% | -7.49M -- | 909.78K -- | -6.84M -- | -5.53M -39.42% | -4.42M +40.90% | -1.48M -262.53% | -5.88M +13.97% | -5.21M +5.85% | -5.73M -29.47% | 1.00M +119.26% | -4.06M +29.18% | -2.87M -- | -4.35M -- | -5.29M -627.12% | -7.55M -86.00% | -3.07M -6.89% | -3.58M +17.59% | -3.74M +29.26% | -2.23M +70.47% | -6.44M -109.57% | -15.99M -- |
Total Comprehensive Income Attributable to Owners of the Company | -1.67M -- | -1.67M -- | -48.78M -- | 6.43M -- | -3.18M -89.99% | -6.61M -295.38% | -368.59K +94.42% | -10.29M -- | -12.07M -- | -1.31M -- | -3.66M +64.44% | -7.60M +37.00% | -2.44M -86.72% | -3.97M -62.75% | -7.49M -- | 909.78K -- | -6.84M -- | -5.53M -39.42% | -4.42M +40.90% | -1.48M -262.53% | -5.88M +13.97% | -5.21M +5.85% | -5.73M -29.47% | 1.00M +119.26% | -4.06M +29.18% | -2.87M -- | -4.35M -- | -5.29M -627.12% | -7.55M -86.00% | -3.07M -6.89% | -3.58M +17.59% | -3.74M +29.26% | -2.23M +70.47% | -6.44M -109.57% | -15.99M -- |
Basic EPS | 0 -- | -0.03 -- | -0.06 -- | -- -- | 0 -- | -0.01 +66.67% | 0 +100.00% | -0.01 -- | -0.01 -- | 0 -- | 0 +100.00% | -0.22 -2100.00% | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- |
Diluted EPS | 0 -- | -0.03 -- | -0.06 -- | -- -- | 0 -- | -0.01 +66.67% | 0 +100.00% | -0.01 -- | -- -- | -- -- | 0 +100.00% | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- |
You can ask Aime
What is Akari Therapeutics's latest dividend and current dividend yield?What is Akari Therapeutics's gross profit margin?What were the key takeaways from Akari Therapeutics’s earnings call?What does Akari Therapeutics do and what are its main business segments?What is the market's earnings forecast for Akari Therapeutics next quarter?What is the revenue and EPS growth rate for Akari Therapeutics year over year?Did Akari Therapeutics beat or miss consensus estimates last quarter?What guidance did Akari Therapeutics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
